We attempted to investigate the clinicopathological correlation of renal oncocytoma (RO) with renal vein extension. We identified seven ROs with extension into the branches of renal vein. The age of seven patients ranged from 61 to 82 years. Five cases were identified incidentally; two patients had gross hematuria. After surgery, all patients were alive and free of tumors with follow-up of 1 to 5 years (mean = 3.6). Oncocytomas measured from 2.2 to 7.5 cm. Renal vein extension was grossly suspected in five of seven cases and histologically confirmed in all seven cases. Tumor cells were positive for cytokeratins, mitochondrial-antigen (MIA), epithelial membrane antigen (EMA), and parvalbumin; five of seven tumors were focally positive for CD117. Ultrastructurally, the cytoplasm was packed by mitochondria. Molecular genetic analysis did not detect abnormal numbers of chromosomes 1, 2, 6, 7, 10, 17, and XY by fluorescence in situ hybridization, loss of heterozygosity on 3p and mutation of von Hippel-Lindau gene in all cases. Array comparative genomic hybridization analysis of two cases did not show any major genetic changes. Our conclusions are as follows: (1) renal oncocytomas may have intravascular extension to the branches of the renal vein; (2) renal oncocytomas with intravascular extension to the branches of the renal vein have the same morphological, immunohistochemical, and cytogenetic findings as have their counterparts without evidence of intravascular invasion; (3) the absence of metastases suggests an overall benign behavior of this tumor, but this has to be substantiated by further studies with a long-term follow-up; and (4) in a renal tumor with granular cytoplasm showing renal vein extension, it is necessary to carefully exclude renal cell carcinomas such as chromophobe RCC, oncocytic variant of papillary RCC, and granular variant of clear cell RCC.

Department of Pathology Charles University Hospital Plzen Pilsen Czech Republic

Zobrazit více v PubMed

Ann Diagn Pathol. 2006 Jun;10(3):133-9 PubMed

J Urol. 1988 Mar;139(3):585-7 PubMed

J Urol. 2006 Jun;175(6):2302-6 PubMed

Am J Surg Pathol. 1999 Jul;23(7):772-80 PubMed

Br J Urol. 1996 Jun;77(6):927-8 PubMed

J Comput Assist Tomogr. 1986 Nov-Dec;10(6):1054-6 PubMed

Semin Diagn Pathol. 1998 Feb;15(1):21-40 PubMed

Arch Pathol Lab Med. 2002 May;126(5):610-2 PubMed

J Urol. 1993 Nov;150(5 Pt 1):1380-3 PubMed

Am J Surg Pathol. 1997 Aug;21(8):871-83 PubMed

Adv Anat Pathol. 1999 Jan;6(1):1-11 PubMed

Am J Surg Pathol. 1997 Jan;21(1):1-12 PubMed

Br J Urol. 1988 Jul;62(1):89-90 PubMed

Am J Surg Pathol. 2005 Dec;29(12):1576-81 PubMed

Am J Surg Pathol. 2002 Mar;26(3):281-91 PubMed

Mod Pathol. 2005 Feb;18(2):161-9 PubMed

J Pathol. 1997 Oct;183(2):131-3 PubMed

Cancer. 1997 Sep 1;80(5):987-9 PubMed

Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases